Figure 3.

ASO21 reduces Hs 578T viability and enhances chemosensitivity of TNBC. (a) ASO21 decreases Hs 578 cellular viability in dose dependent manner. Hs 578T cells were treated with ASO21 and scrambled-ASO (SCR) at various concentrations (200 nM, 300 nM, 400 nM). Three days after the second transfection, cell proliferation was assayed by alamar blue. (b). Representative images of Hs 578T cells that were treated with control-ASO or menin-ASO (ASO21). (c) ASO21 enhances chemosensitivity of Hs 578T cell to Docetaxel. After the second ASO transfection at 200 nM 2 days, Docetaxel 100 nM was added and incubated for 2 days before the MTT tests. Menin knockdown using ASO 21 increased cellular sensitivity to Docetaxel since cell survival decreased significantly with combination of this chemodrug with menin-ASO compared with monotherapy using menin-ASO alone was considered significant, with *** p ≤ 0.001.